PhD Thesis_ver3.pdf

More documents

Recommendations

Info

Сравнително in vitro изследване на нови възможности за фармакологично повлияване на мултипления миелом antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1." J Clin Oncol 25(11): 1390-5. 249. Tonon, G. (2007). "Molecular pathogenesis of multiple myeloma." Hematol Oncol Clin North Am 21(6): 985-1006, vii. 250. Trudel, S., Z. H. Li, J. Rauw, R. E. Tiedemann, X. Y. Wen, et al. (2007). "Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma." Blood 109(12): 5430-8. 251. Trudel, S., A. K. Stewart, Z. Li, Y. Shu, S. B. Liang, et al. (2007). "The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan." Clin Cancer Res 13(2 Pt 1): 621-9. 252. Tu, Y., S. Renner, F. Xu, A. Fleishman, J. Taylor, et al. (1998). "BCL-X expression in multiple myeloma: possible indicator of chemoresistance." Cancer Res 58(2): 256-62. 253. Tu, Y., F. H. Xu, J. Liu, R. Vescio, J. Berenson, et al. (1996). "Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide." Blood 88(5): 1805-12. 254. van Blitterswijk, W. J. and M. Verheij (2008). "Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects." Curr Pharm Des 14(21): 2061-74. 255. Van Ummersen, L., K. Binger, J. Volkman, R. Marnocha, K. Tutsch, et al. (2004). "A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer." Clin Cancer Res 10(22): 7450-6. 256. Varma, R. and S. Mayor (1998). "GPI-anchored proteins are organized in submicron domains at the cell surface." Nature 394(6695): 798-801. 257. Verstovsek, S., F. Giles, A. Quintas-Cardama, N. Perez, F. Ravandi-Kashani, et al. (2006). "Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?" Hematol Oncol 24(4): 181-8. 258. Vink, S. R., J. H. Schellens, W. J. van Blitterswijk and M. Verheij (2005). "Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid." Invest New Drugs 23(4): 279-86. 259. Vink, S. R., W. J. van Blitterswijk, J. H. Schellens and M. Verheij (2007). "Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy." Cancer Treat Rev 33(2): 191-202. 260. Voorhees, P. M., Q. Chen, D. J. Kuhn, G. W. Small, S. A. Hunsucker, et al. (2007). "Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma." Clin Cancer Res 13(21): 6469-78. 261. Voorhees, P. M., Q. Chen, G. W. Small, D. J. Kuhn, S. A. Hunsucker, et al. (2009). "Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death." Br J Haematol 145(4): 481-90. 262. Wakelee, H. A., A. Patnaik, B. I. Sikic, M. Mita, N. L. Fox, et al. (2010). "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors." Ann Oncol 21(2): 376-81. 263. Wan, C. K., C. Wang, H. Y. Cheung, M. Yang and W. F. Fong (2006). "Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells." Cancer Lett 241(1): 31-41. 264. Wang, Z. Y. and Z. Chen (2008). "Acute promyelocytic leukemia: from highly fatal to highly curable." Blood 111(5): 2505-15. 265. Ward, P. D., H. Ouyang and D. R. Thakker (2003). "Role of phospholipase C-beta in the modulation of epithelial tight junction permeability." J Pharmacol Exp Ther 304(2): 689-98. 266. Webb, J. L. (1963). Enzyme and metabolic inhibitors. New York,, Academic Press. 267. Wen, J., Y. Feng, W. Huang, H. Chen, B. Liao, et al. (2010). "Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition." Leuk Res 34(1): 85-92. 324
325 VII. Библиография 268. Xiao, H., Q. Xiao, K. Zhang, X. Zuo and U. K. Shrestha (2010). "Reversal of multidrug resistance by curcumin through FA/BRCA pathway in multiple myeloma cell line MOLP-2/R." Ann Hematol 89(4): 399-404. 269. Yaccoby, S., M. J. Wezeman, M. Zangari, R. Walker, M. Cottler-Fox, et al. (2006). "Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model." Haematologica 91(2): 192-9. 270. Yasui, H., T. Hideshima, H. Ikeda, J. Jin, E. M. Ocio, et al. (2007). "BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth." Br J Haematol 136(3): 414-23. 271. Yeh, H. S. and J. R. Berenson (2006). "Treatment for myeloma bone disease." Clin Cancer Res 12(20 Pt 2): 6279s-6284s. 272. Yoshida, K., Y. Miki and D. Kufe (2002). "Activation of SAPK/JNK signaling by protein kinase Cdelta in response to DNA damage." J Biol Chem 277(50): 48372-8. 273. Zhou, L., J. Hou, W. Fu, D. Wang, Z. Yuan, et al. (2008). "Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib." Leuk Res 32(11): 1674-83. 274. Zhou, Y., B. Barlogie and J. D. Shaughnessy, Jr. (2009). "The molecular characterization and clinical management of multiple myeloma in the post-genome era." Leukemia 23(11): 1941- 56.
Page 1:
МЕДИЦИНСКИ УНИВЕРС
Page 4 and 5:
Сравнително in vitro и
Page 6 and 7:
Page 8 and 9:
Page 10 and 11:
Page 13 and 14:
Увод Мултипленият
Page 15 and 16:
15 I. Литературен обз
Page 17 and 18:
Page 19 and 20:
VEGF и bFGF TNFα IL-6 СКМК TN
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
1.6.7. Инхибитори на Hs
Page 45 and 46:
Page 47 and 48:
1.7. Заключение 47 I. Л
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
2.5.7. Непреки механи
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
3. Куркумин 3.1. Добив
Page 67 and 68:
3.3.1. Пряко взаимоде
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
II. ЦЕЛ И ЗАДАЧИ 1. Це
Page 87 and 88:
III. МАТЕРИАЛИ И МЕТО
Page 89 and 90:
89 III. Материали и ме
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
среда, предварител
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
хранителна среда. 10
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
до 6. 113 III. Материали
Page 115 and 116:
броя на пробите. 4. Т
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
ресуспендирани ядр
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
2.16.2. Пречистване на
Page 147 and 148:
2.17.1. Трансфекция с
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
IV. РЕЗУЛТАТИ 1. Клет
Page 155 and 156:
IV. Резултати - Клетъ
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
IV. Резултати - Механ
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
А IV. Резултати - Мех
Page 205 and 206:
Page 207 and 208:
Erufosine, µM: А Erufosine, µM:
Page 209 and 210:
А Б IV. Резултати - Ме
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
OPM-2 Относително нив
Page 223 and 224:
RPMI-8226 Относително н
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
60 50 40 30 20 10 IV. Резулт
Page 231 and 232:
3. Влияние на различ
Page 233 and 234:
IV. Резултати - Влиян
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Фиг. IV.73. Влияние на
Page 249 and 250:
Фиг. IV.74. Влияние на
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
тромбин: IV. Резулта
Page 259 and 260:
Page 261 and 262:
Б IV. Резултати - Вли
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Мигрирали клетки, %
Page 271 and 272:
Page 273 and 274: IV. Резултати - Влиян
Page 275 and 276: % на преживелите кл
Page 279 and 280: U-266 - + - + - - 20 20 IV. Рез
Page 283 and 284: Гъстота на клеткит
Page 285 and 286: V. ОБСЪЖДАНЕ НА РЕЗУ
Page 287 and 288: 287 V. Обсъждане на ре
Page 309 and 310: 309 VI. Изводи 6. Еруфо
Page 311 and 312: VII. БИБЛИОГРАФИЯ 1. Ab
Page 313 and 314: 313 VII. Библиография 3
Page 323: 323 VII. Библиография 2
Page 327 and 328: 076) Стерилни епруве
Page 329 and 330: 2.3. За оценка на адх
Page 331 and 332: 331 VIII. Приложение I
Page 333 and 334: 1 M MOPS; 1 M Трис; 2% SDS; 20
Page 335 and 336: 335 VIII. Приложение I Ak
Page 337 and 338: 337 VIII. Приложение I Go
Page 339 and 340: 339 VIII. Приложение I 6.
Page 341 and 342: pH на буфера трябва
Page 343 and 344: - 5`-праймер: 5` - ЦГЦ А
Page 345 and 346: 345 VIII. Приложение I T
Page 347 and 348: 10× TBE-буфер, приготв
show all

PhD Thesis_ver3.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?